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Abstract
Background: Long non-coding RNAs (lncRNAs) exhibit highly cell type-specific expression and function, making
this class of transcript attractive for targeted cancer therapy. However, the vast majority of lncRNAs have not been
tested as potential therapeutic targets, particularly in the context of currently used cancer treatments. Malignant
glioma is rapidly fatal, and ionizing radiation is part of the current standard-of-care used to slow tumor growth in
both adult and pediatric patients.
Results: We use CRISPR interference (CRISPRi) to screen 5689 lncRNA loci in human glioblastoma (GBM) cells,
identifying 467 hits that modify cell growth in the presence of clinically relevant doses of fractionated radiation.
Thirty-three of these lncRNA hits sensitize cells to radiation, and based on their expression in adult and pediatric
gliomas, nine of these hits are prioritized as lncRNA Glioma Radiation Sensitizers (lncGRS). Knockdown of lncGRS-1, a
primate-conserved, nuclear-enriched lncRNA, inhibits the growth and proliferation of primary adult and pediatric
glioma cells, but not the viability of normal brain cells. Using human brain organoids comprised of mature neural
cell types as a three-dimensional tissue substrate to model the invasive growth of glioma, we find that antisense
oligonucleotides targeting lncGRS-1 selectively decrease tumor growth and sensitize glioma cells to radiation
therapy.
Conclusions: These studies identify lncGRS-1 as a glioma-specific therapeutic target and establish a generalizable
approach to rapidly identify novel therapeutic targets in the vast non-coding genome to enhance radiation
therapy.
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Background
The human genome produces many thousands of
lncRNAs [1–3]—transcripts longer than 200 nucleotides
that do not encode for proteins—and certain lncRNAs
play key roles in the pathogenesis of cancer [4–7].
LncRNAs exhibit highly cell type-specific expression and
function [1, 8], making this class of transcripts attractive
for targeted cancer therapy. However, it is currently not
possible to predict which of these non-coding transcripts
would be effective therapeutic targets, let alone those
that could sensitize cancer cells to radiation. To rapidly
develop lncRNAs as a class of targets for cancer therapy,
systematic functional screens are necessary.
CRISPR-based technologies have enabled genome-scale
screens of gene function in mammalian cells [8–16].
These screening methods have been valuable to the identi-
fication of genes—non-coding in addition to coding—that
are essential for various cellular phenotypes. However,
whether such screen-identified hits can increase the effi-
cacy of ionizing radiation—a critical adjunctive cancer
therapy for many malignancies—has not been systematic-
ally studied at large scale.
Malignant glioma—a primary cancer of the central
nervous system (CNS)—is a fatal diagnosis for most pa-
tients [17]. Despite surgery and adjuvant therapy such as
fractionated radiation, adults with glioblastoma (GBM)
have a median survival of only 14 months [18, 19]. In
children, the most common malignant glioma is diffuse
intrinsic pontine glioma (DIPG). DIPG is primarily
treated with radiotherapy, but median survival is only 9–
10months, and few patients survive more than 2 years
after diagnosis [20–22]. While radiation is a critical com-
ponent of the treatment of both adult and pediatric ma-
lignant gliomas by reducing tumor growth [19, 23, 24],
the toxicity of radiation to normal brain cells limits the
total dose that can be delivered, and glioma cells that
survive radiation lead to tumor recurrence. Thus, thera-
peutics that increase the efficacy of radiation without re-
ducing the viability of normal brain cells would be of
critical clinical benefit, complementing the current
standard-of-care for nearly all patients with malignant
gliomas.
Organoids are miniature three-dimensional (3D) rep-
resentations of their in vivo counterpart organs, and
organoid-based models of cancer are emerging as a use-
ful platform for the evaluation of therapeutics [25]. Hu-
man brain organoids have been generated from
pluripotent stem cell (PSC) populations, mimicking early
stages of fetal brain development [26–28]. Such embry-
onic brain organoids have been useful to study the gen-
etic mutations that cause GBM [29] and can also serve
as a 3D tissue substrate for the growth of glial tumors
[30]. However, embryonic brain organoids do not closely
represent the mature brain tissue of glioma patients,
limiting their utility for assessing potential drug toxicity
to normal adult brain cells.
Here, we developed a radiation modifier screen using
CRISPRi to identify specific lncRNAs that sensitize gli-
oma cells to radiotherapy. In this screen of 5689 lncRNA
loci, 467 hits were found to modify cell growth in the
presence of radiation. Thirty-three of these hits sensi-
tized cells to clinically relevant doses of fractionated ra-
diation, and based on their expression in adult and
pediatric glioma, nine of these hits were prioritized as
lncRNA Glioma Radiation Sensitizers (lncGRS). Knock-
down of lncGRS-1 (CTC-338M12.4 located on chromo-
some 5 q35.3) inhibited the growth of primary adult and
pediatric glioma cells, but the viability of normal brain
cells was not harmed. While lncGRS-1 is primate-
conserved, this lncRNA does not exist in rodents, mak-
ing traditional in vivo mouse models of glioma subopti-
mal for assessing potential toxicity of lncGRS-1
knockdown in normal brain tissue. We therefore devel-
oped a novel human brain organoid model of malignant
glioma. To mimic the brains of patients, we assembled
“mature” human brain organoids (MBOs) from mature
neural cell types derived from induced pluripotent stem
cells (iPSCs), and human glioma cells grew invasively
within these 3D tissues. Furthermore, antisense oligonu-
cleotides (ASOs) targeting lncGRS-1 selectively de-
creased tumor growth and sensitized glioma cells to
radiation therapy. These studies identify lncGRS-1 as a
glioma-specific therapeutic target and establish a
generalizable approach to rapidly identify novel thera-
peutic targets in the vast non-coding genome.
Results
A CRISPRi platform for radiotherapy sensitization in a
glioma cell culture model
To systematically identify lncRNAs as potential thera-
peutic targets that sensitize malignant glioma to radio-
therapy, we developed a radiation modifier screen using
CRISPRi for gene knockdown. CRISPRi represses tran-
scription via the recruitment of catalytically “dead” Cas9
protein fused to the KRAB repressor (dCas9-KRAB),
which is targeted to transcriptional start sites (TSS) by a
single guide RNA (sgRNA) [11, 31, 32]. For the screen,
we used a workhorse GBM cell line (U87) engineered to
stably express dCas9-KRAB (U87-dCas9-KRAB) to iden-
tify hits for subsequent study in patient-derived cultures
of pediatric and adult forms of malignant glioma.
First, we sought to determine a radiation dose and de-
livery schedule in U87-dCas9-KRAB cells that enables
the discovery of radiation-effect modifiers. For the treat-
ment of human GBM patients, the total radiation dose is
typically delivered in ~ 2 Gy daily fractions [18, 19].
When 2 Gy was delivered to U87-dCas9-KRAB cells as a
single dose, cell proliferation transiently decreased but
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returned to normal after 8–10 days (Fig. 1a). A single
dose of 4 or 8 Gy had correspondingly stronger and
more prolonged inhibitory effects upon cell proliferation
(Fig. 1a), and RNA-seq analysis revealed dose-dependent
gene expression changes including induction of the
p53 pathway and repression of DNA replication
(Additional file 1: Fig. S1a). However, these higher
single doses exceed those typically used for patients
with malignant glioma. Thus, we also tested a total
radiation dose of 8 Gy delivered in 2 Gy fractions
given every other day (8 Gy in 4 fractions). This 8 Gy
fractionated dose increased the cell doubling time by
approximately 2-fold, which is an effect size approxi-
mating LD50 (Fig. 1a), which allows optimal discovery
of both synergistic and buffering screen hits [33],
while still utilizing a clinically relevant fractional dose
of 2 Gy.
We next tested whether U87-dCas9-KRAB cells treated
with 8 Gy fractionated radiation can reveal radiation
sensitization effects with CRISPRi gene targeting. The in-
hibition of DNA repair pathways is known to potentiate
the therapeutic effects of radiation in cancer cells [34, 35].
In internally controlled growth assays [8, 11], two distinct
CRISPRi sgRNAs targeting the DNA damage repair gene
ERCC6L2 [36, 37] reduced cell growth in U87 cells treated
with 8 Gy fractionated radiation (Fig. 1b). Without radi-
ation treatment, CRISPRi targeting of ERCC6L2 did not
reduce cell growth (Fig. 1c). Thus, CRISPRi targeting of
the DNA repair gene ERCC6L2 produces a strong radi-
ation sensitization effect in this in vitro model of fraction-
ated radiotherapy.
CRISPRi screen identifies lncRNA Glioma Radiation
Sensitizer hits
Although disruption of known DNA repair pathways is
an intriguing avenue for novel therapeutics, accumula-
tion of unrepaired DNA damage may paradoxically in-
crease cancer risk [38, 39]. The human genome
produces thousands of lncRNAs that represent a large
set of novel potential therapeutic targets. We screened
the function of 5689 lncRNAs expressed in human gli-
oma by leveraging our CRISPRi Non-Coding Library [8],
selecting 10 sgRNAs for each lncRNA TSS and cloning
this pool of 56,890 sgRNAs into lentiviral vectors along
with 1202 non-targeting control sgRNAs (Fig. 2a). We
used this lentiviral sgRNA library to infect two replicates
of U87-dCas9-KRAB cultures, selected for infected cells
with puromycin, treated cultures with 8 Gy fractionated
Fig. 1 A glioma cell culture model for identifying radiation sensitizers. a Doubling time of U87 GBM cells in culture after treatment with different
amounts of single-dose or fractionated radiation. Fractionated (fx) radiation (8 Gy in 4 fx) was delivered in 2 Gy doses every other day (n = 3
biological replicates per condition; error bar = SD). b, c Internally controlled growth assays for U87 cells evaluating CRISPRi knockdown of ERCC6L2
with (b) and without (c) radiation (n = 3 biological replicates per condition; error bar = SD; two-tailed Student’s t test of end points; radiation
delivery timepoints indicated below the x-axis)
Liu et al. Genome Biology           (2020) 21:83 Page 3 of 18
radiation, then continued cell propagation for a total of
12 days. The proportion of sgRNA positive cells remained
stable throughout the screen, indicating that CRISPRi tar-
geting does not exhibit non-specific toxicity even after ra-
diation treatment (Additional file 1: Fig. S2a).
Targeted next generation sequencing of sgRNA barcodes
performed at the beginning and end of the screen (~ 7.1 cell
doublings) identified 652 loci that modified cell growth and
proliferation in the presence of radiation as compared to
the effect of radiation alone (FDR = 0.25%). One hundred
eighty-five of these lncRNA TSS hits were within 1 kb of an
expressed protein-coding gene and therefore conservatively
labeled as “neighbor hits,” with the 1 kb window around the
TSS being based on analyses of CRISPRi mechanism and
maximum effective distance for knockdown [8, 11]. These
neighbor hits were removed from further analysis, leaving
467 “lncRNA hits” that modified the propagation of
radiation-treated U87 cells (Fig. 2b; Additional file 2:
Table S1). Interestingly, CRISPRi-mediated knockdown
of the lncRNA PVT1 protected cells against the effect of
radiation (Additional file 1: Fig. S2b), consistent with
PVT1 acting as a negative regulator of MYC [40]. The
other 466 lncRNA hits negatively affected cell culture
growth when combined with radiation.
Fig. 2 CRISPRi radiation modifier screen in glioma cells. a Experimental design. Eight Gy radiation was delivered in 4 fractions throughout the
screen. b Volcano plot of radiation growth phenotypes (average of two replicate screens) for the top 3 sgRNAs targeting each lncRNA TSS (x-axis)
and negative log10(Mann-Whitney U p value) of all sgRNAs for a given gene at T12 as compared to T0 (y-axis). Screen threshold was determined
by the product of the x- and y-axes that resulted in an empirical FDR of 0.0025. Neighbor hits are defined as any lncRNA hit with an expressed
protein coding gene within 1 kb of the lncRNA TSS. Phenotype refers to the relative log2 enrichment of barcodes in the final timepoint divided
by the enrichment of barcodes at the initial timepoint [8, 11]. c Comparison of screen scores, defined as the average phenotype of the top three
sgRNAs against a given gene multiplied by the negative log10(Mann-Whitney U p value) for that gene, from screens conducted without radiation
(x-axis) with scores from screens conducted with radiation (y-axis), with thresholds set at 5 (FDR = 0.0025). Thirty-three lncRNA hits had radiation
screen scores greater than no radiation screen scores. CTC-338 M12.4 (lncGRS-1) is indicated. d LncRNA expression across 2 DIPG and 3 GBM
cultures (subpanel 1), no radiation screen scores (subpanel 2), radiation screen scores (subpanel 3), and sensitizer scores (subpanel 4) for each of
the 9 lncGRS candidates. Sensitizer score is defined as the ratio of the radiation modifier screen score in irradiated cells to the growth screen
score in non-irradiated cells
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To identify lncRNA hits that sensitized cells to the ef-
fect of radiation, we compared the screen scores (defined
as the average phenotype of the top three sgRNAs
against a given gene multiplied by the negative log10(-
Mann-Whitney U p value) for that gene) for the radi-
ation modifier screen with the growth screen scores
from U87 cells that were not irradiated [8]. Phenotype in
these CRISPRi screens refers to the relative log2 enrich-
ment of barcodes in the final timepoint divided by the
enrichment of barcodes at the initial timepoint [8, 11].
Thirty three hits identified in both screens had screen
scores that were greater in the radiation modifier screen
(Fig. 2c). Interestingly, the expression of these 33
sensitizer lncRNA hits tended to be downregulated fol-
lowing exposure to 8 Gy of radiation (Pearson’s R =
0.36), which was not observed for the larger set of 467
hits (Pearson’s R = 0.079) (Additional file 1: Fig. S2c),
suggesting that transcriptional repression following radi-
ation may be a common feature of lncRNA radiosensiti-
zers. Nine of these 33 sensitizer hits were expressed in a
panel of various malignant glioma cells including both
adult GBM (U87, SF10360, SF10281) and pediatric DIPG
(SF8628, SF10218). We ranked these nine hits by a
“sensitizer score,” which we defined as the ratio of the
radiation modifier screen score in irradiated cells to the
growth screen score in non-irradiated cells, and denoted
these genes as lncRNA Glioma Radiation Sensitizers
(lncGRS) 1 to 9 (Fig. 2d). To more accurately survey the
transcript structure(s) of these hits, we performed long-
read single molecule native RNA sequencing using the
Oxford Nanopore PromethION and defined transcript
variants and splice boundaries of lncGRS-1 through
lncGRS-9 (Fig. 3a, Additional file 1: Fig. S3).
CRISPRi-mediated knockdown of lncGRS-1 synergizes with
fractionated radiation
lncGRS-1 encodes spliced, poly-adenylated tran-
scripts (687 to 1013 bp) from chromosome 5 (Fig. 3a,
Additional file 1: Fig. S3). Although previously anno-
tated (CTC-338M12.4) [41], this lncRNA’s biological func-
tion was not known. Cell fractionation analysis (Fig. 3b) and
in situ hybridization studies (Fig. 3c, Additional file 1: S4a)
revealed lncGRS-1 to be a nuclear-enriched transcript in gli-
oma cells, including those of patient-derived, primary glioma
cultures. Furthermore, lncGRS-1 transcription is downregu-
lated following radiation (Additional file 1: Fig. S1b).
In internally controlled growth assays of U87 cell
growth, CRISPRi-mediated knockdown of lncGRS-1 with
two different, individual sgRNAs (Fig. 3d) reduced cell
proliferation by ~ 48% in the absence of radiation
(Fig. 3e). Treatment of cells with 8 Gy fractionated radi-
ation alone decreased cell proliferation (Fig. 1a), and
lncGRS-1 knockdown further reduced cell proliferation
by ~ 37% relative to radiation alone (Fig. 3f). We also
purified U87-dCas9-KRAB cells that express sgRNA against
lncGRS-1 or non-targeting control sgRNAs and studied the
growth of these cultures with and without 8Gy fractionated
radiation. Without radiation, sgRNAs against lncGRS-1 re-
duced cell proliferation by 42% (Fig. 3g), and radiation
alone reduced the proliferation of cells expressing control
sgRNAs by 71% (Fig. 3g, h). When combined, lncGRS-1
knockdown and radiation treatment resulted in a pro-
nounced 95% decrease in proliferation (Fig. 3h), indicating
synergy of the two treatments, as the predicted decrease in
cell proliferation from an additive effect model is only 83%
(p = 0.0052; see the “Methods” section).
CRISPRi- and antisense oligonucleotide-mediated lncGRS-
1 knockdown inhibits the growth of glioma cells from
both adult and pediatric patients
We next sought to validate lncGRS-1 as a potential thera-
peutic target in patient-derived cultures of malignant gli-
oma. We generated human adult GBM (SF10360) and
pediatric DIPG (SF8628) cells stably expressing dCas9-
KRAB and studied the effect of CRISPRi-mediated lncGRS-
1 knockdown in internally controlled growth assays. In
both GBM SF10360 and DIPG SF8628 cells, lncGRS-1
knockdown produced growth inhibition (Fig. 4a, b) similar
to that observed in U87 cultures. Thus, CRISPRi targeting
of lncGRS-1 slows the growth of GBM cell lines and pri-
mary malignant glioma cells in culture.
Antisense oligonucleotides (ASOs) degrade complemen-
tary RNAs via a ribonuclease H-based mechanism, are ef-
fective for the knockdown of nuclear lncRNAs [42], and are
currently used to treat human CNS diseases [43, 44]. To
confirm the ability of ASOs to efficiently deplete gene ex-
pression, we used ASOs to knockdown TP53 (p53) in U87
cells and observed ~ 99% knockdown efficiency (Add-
itional file 1: Fig. S4b). We then designed locked nucleic
acid ASOs against lncGRS-1 (Additional file 1: Fig. S4c,
Additional file 3: Table S2) and tested them for efficacy in
patient-derived glioma cell cultures. Two different ASOs
against lncGRS-1 produced a mean knockdown of 89% in
patient-derived GBM SF10360 cells and 93% in patient-
derived DIPG SF8628 cells (Fig. 4c). Cell proliferation was
decreased by an average of 80% across both ASOs in both
SF10360 and SF8628 by 11 days post-transfection (Fig. 4d).
ASO-mediated knockdown of lncGRS-1 also decreased the
proliferation of patient-derived DIPG cultures SU-DIPG 24,
SU-DIPG 25 (Additional file 1: Fig. S4d,e), and GBM 43
(Additional file 1: Fig. S4f). Thus, ASOs targeting lncGRS-1
inhibit the growth of multiple human patient-derived cul-
tures of malignant glioma.
ASO-mediated knockdown of lncGRS-1 is not toxic to
human astrocytes
Current standard-of-care treatments for glioma are lim-
ited by toxicity to normal tissues [23]. Consistent with
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lncRNAs having exquisitely cell type-specific essential
function [8], ASO-mediated knockdown of lncGRS-1 did
not affect the proliferation of the kidney-derived
HEK293T cell line (Additional file 1: Fig. S4g). Astro-
cytes are the most numerous cell type of the human brain
[45] and are phenotypically related to subpopulations of
malignant glioma [46, 47]. We therefore next investigated
the effect of lncGRS-1 knockdown in cultures of normal
human astrocytes (NHAs) [48]. Knockdown of essential
gene POLA1 (DNA polymerase alpha 1) resulted in de-
creased proliferation of NHA cells, in addition to U87
GBM cells (Additional file 1: Figure S4h,i). While ASO-
Fig. 3 lncGRS-1 is a primate-conserved radiation sensitizer target in glioma. a Nanopore direct RNA-seq spliced reads aligned to the lncGRS-1
gene body in U87 cells, with GENCODE v29 transcript models of lncGRS-1 (CTC-338 M12.4) and multiz alignment for conservation. b Subcellular
fractionation followed by qPCR of transcripts in U87 cells. c Single molecule FISH of lncGRS-1 in GBM SF10360 and DIPG SF8628 primary glioma
cells. Scale bar = 5 μm. d RT-qPCR for lncGRS-1 after CRISPRi targeting in U87 (n = 2 biological replicates; error bar = SD). e, f Internally controlled
growth assays of U87 cells with CRISPRi knockdown of lncGRS-1 in the absence (e) and presence (f) of fractionated radiation. g, h Cell
propagation assay of purified populations of U87 cells with lncGRS-1 CRISPRi knockdown in the absence (g) and presence (h) of fractionated
radiation. For e–h, n = 2 biological replicates per condition; error bars = SD; two-tailed Student’s t test. N.S., not significant. Radiation delivery
timepoints indicated below the x-axis
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mediated lncGRS-1 knockdown was robustly achieved in
NHA (Fig. 5a), cell proliferation was not reduced (Fig. 5b).
Moreover, in NHA, measures of cell viability and apop-
tosis were not changed by lncGRS-1 knockdown, whereas
in patient-derived glioma cells, viability was decreased,
and apoptosis was increased (Fig. 5c). Finally, CRISPRi-
mediated knockdown of lncGRS-1 with the same two
sgRNAs used for knockdown in U87 cells did not result in
decreased proliferation in HeLa cervical cancer cells stably
expressing dCas9-KRAB (Additional file 1: Fig. S5a), des-
pite these cells expressing lncGRS-1 at a robust level
(TPM= 4.38) among the CCLE compendium of cancer
cell lines (Additional file 1: Fig. S5b) [49].
To investigate the glioma-specific phenotype of
lncGRS-1, we performed RNA-seq analysis following
ASO-mediated lncGRS-1 knockdown. In GBM (U87),
DIPG (SF8628), and NHA cells, lncGRS-1 expression
was decreased by 80–88% 24 h after ASO treatment
(Fig. 5e). Consistent with the changes in viability
and apoptosis observed with lncGRS-1 knockdown,
both GBM and DIPG cells exhibited transcriptome-wide
differential gene expression (984 and 3600 genes adj. p <
0.05, respectively; Fig. 5e, Additional file 4: Table S3). Up-
regulated genes in U87 and SF8628 were enriched for p53
signaling and apoptosis, while downregulated genes were
enriched for cell cycle and DNA damage response
(Additional file 1: Fig. S5c). Despite different gene ontol-
ogy terms, differentially expressed genes between U87 and
SF8628 cells were positively correlated following knock-
down of lncGRS-1 (Pearson’s R = 0.667; Additional file 1:
Fig. S5d). Consistent with these genome-wide changes,
levels of CDKN1A (p21) increased at the level of both
mRNA and protein following lncGRS-1 knockdown in
U87 cells (Additional file 1: Fig. S5e,f, Additional file 1:
Fig. S6). These cells also exhibited decreased proportions
of G2/M phase in population-level flow cytometry
(Fig. 5d). Interestingly, while lncGRS-1 knockdown re-
sulted in increased p53BP1 foci in U87 cells in the absence
of radiation, γH2AX foci induced by radiation were poten-
tiated by knockdown of lncGRS-1, yet lncGRS-1 knock-
down in the absence of radiation did not generate
additional γH2AX foci (Additional file 1: Fig. S5g,h). Re-
markably, while ASOs were effective for lncGRS-1 knock-
down in NHA, such genome-wide changes to the
Fig. 4 lncGRS-1 is required for the proliferation of primary, patient-derived glioma cells. a RT-qPCR of lncGRS-1 transcript levels following CRISPRi-
mediated knockdown in GBM SF10360 and DIPG SF8628 (n = 2 biological replicates per condition; error bars = SD). b Internally controlled, growth
assays of GBM SF10360 and DIPG SF8628 cells with CRISPRi-mediated knockdown of lncGRS-1 (n = 2 biological replicates per condition; error
bars = SD). c RT-qPCR of lncGRS-1 transcript levels following ASO-mediated knockdown of GBM SF10360 and DIPG SF8628 (n = 2 biological
replicates per condition; error bars = SD). d Cell propagation time course of GBM SF10360 and DIPG SF8628 cells with ASO-mediated knockdown
of lncGRS-1. ASOs were re-transfected at day 7 (n = 2 biological replicates per condition; error bars = SD)
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transcriptome were not observed in these non-
tumorigenic cells (Fig. 5e).
ASOs targeting lncGRS-1 decrease glioma tumor growth
in mature brain organoids
While the genomic sequences of lncGRS-1 are conserved
across primates, orthologs of this lncRNA do not exist
in lower vertebrates such as mice, chicken, and zebrafish
(Fig. 3a, Additional file 1: Fig. S3). Therefore, evaluating
the potential toxicity of lncGRS-1 knockdown in normal
postnatal brain necessitates an alternative to xenograft
mouse models. Recent studies have shown that embry-
onic cerebral organoids can serve as 3D tissue “hosts”
for the growth of human glioma cells [30]. However,
Fig. 5 lncGRS-1 function is glioma specific. a RT-qPCR of lncGRS-1 transcript levels following ASO-mediated knockdown in NHA cells (n = 2
biological replicates per condition; error bars = SD). b Cell propagation time course in NHA cells with ASO-mediated knockdown of lncGRS-1.
ASOs were re-transfected at day 7 (n = 2 biological replicates per condition; error bars = SD). c Left, fluorescence viability assay of malignant tumor
cells and NHA cells following ASO-mediated lncGRS-1 knockdown. Right, apoptosis assay of malignant tumor cells and NHA cells following ASO-
mediated lncGRS-1 knockdown (n = 2 biological replicates per condition; error bars = SD). d Cell cycle phase analysis following lncGRS-1
knockdown in GBM U87 using flow cytometry. e RNA-seq differential gene expression analysis of lncGRS-1 knockdown in GBM U87 (left), DIPG
SF8628 (middle), and NHA (right) cells using lncGRS-1 ASO #1 and ASO #2 as biological replicates, compared to negative control ASO, 24 h
following transfection (n = 2 biological replicate cultures per ASO condition). Green, genes adj. p value < 0.05. Red triangle, lncGRS-1
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such embryonic brain organoids are comprised mostly
of immature, proliferative neural progenitors and con-
tain very few astrocytes [50–52], which are a type of glia
essential to neuronal viability and function [53]. We
therefore generated “mature” human brain organoids
(MBOs) that more closely reflect the differentiated cellu-
lar state of the postnatal human brain (Fig. 6a).
Astrocytes are the most abundant cell type of the adult
human brain [53]. We generated pure populations of
mature human astrocytes from human iPSCs (iAstro-
cytes) using a protocol that allows maturation for at least
6 months [54, 55]. Using an isogenic iPSC (WTC11)
clone that carries an inducible Neurogenin2 (NGN2)
transgene, we also generated homogenous cultures of
mature cortical neurons (i3Neurons) with NGN2 induc-
tion [54, 56]. MBOs can be formed from iAstrocytes and
i3Neurons by mixing and co-culture of these cell types
in defined numbers and ratios (from a 1:1 ratio to solely
iAstrocytes or i3Neurons) (Fig. 6a) [55].
To build upon our studies of NHAs in 2D culture, we
first studied MBOs assembled from iAstrocytes (A-
MBOs). Unlike astrocytes in 2D culture, iAstrocytes in
MBOs become highly ramified and develop complex
structures similar to those observed in human brain tis-
sue [55]. Transfection of A-MBOs with ASOs against
lncGRS-1 was effective for its knockdown as assessed by
both in situ hybridization, demonstrating depletion of
lncGRS-1 within nuclei (Fig. 6b), and RT-qPCR (Fig. 6c,
Additional file 1: Fig. S7a). Similar to our results from
NHAs in 2D culture (Fig. 5a–c), ASO-mediated lncGRS-
1 knockdown in A-MBOs did not reduce organoid via-
bility or increase apoptosis (Fig. 6d).
We next used A-MBOs as the “host” for human gli-
oma tumor growth (Fig. 6e). After DIPG SF8628 cells la-
beled with red fluorescent protein (RFP) were seeded to
the surface of these MBOs, RFP+ tumors grew progres-
sively larger within the organoid tissue in an invasive
manner, when individually monitored using serial micro-
scopic imaging (Fig. 6f). For treatment of a human CNS
disease, ASOs are administered weekly directly into the
cerebrospinal space [57]. Mimicking this dosing sched-
ule, we added ASOs into the organoid culture media
every 7 days. In each organoid, the growth of RFP+ tu-
mors was prospectively imaged (Fig. 6f, g), and tumor
burden was estimated by quantification of the RFP sig-
nal. ASOs against lncGRS-1 reduced DIPG tumor
growth as compared to non-targeting, negative control
ASOs (Fig. 6h). Consistent with our results of organoid
viability and apoptosis without infiltrated tumor cells
(Fig. 6d), the overall size of the host brain organoid was
not changed by lncGRS-1 knockdown (Fig. 6i).
We further developed the MBO-glioma model by using
MBOs assembled from both iAstrocytes and i3Neurons
(AN-MBOs) and also including radiation therapy. ASO-
mediated knockdown of lncGRS-1 did not affect the viabil-
ity of AN-MBOs (Additional file 1: Fig. S7b). Furthermore,
treatment of AN-MBOs with clinically therapeutic levels
of fractionated radiation (total dose up to 54Gy), with or
without lncGRS-1 knockdown, did not affect the overall
size of organoids over a period of 3 weeks (Additional file 1:
Fig. S7c). Using this AN-MBO model of radiotherapy, we
investigated whether lncGRS-1 knockdown sensitizes gli-
oma cells to the therapeutic effects of radiation. RFP-
labeled U87 cells were seeded to the surface of individual
AN-MBOs isolated across multiple wells of a 96-well dish,
and tumors grew invasively (Additional file 1: Fig. S7d)
and progressively larger when treated with negative con-
trol ASOs and no radiation when tracked using serial
microscopic imaging (Additional file 1: Fig. S7e). As ex-
pected, radiation treatment alone (control ASOs with in-
creasing doses of radiation) exhibited a trend of tumor
inhibition (Fig. 6j). Notably, when radiation (18 Gy in 9
fractions, or 12Gy in 6 fractions) was combined with
ASO-mediated lncGRS-1 knockdown, the tumor burden
was significantly lower than that observed with radiation
alone (Fig. 6j, Additional file 1: Fig. S7e). Thus, ASO-
mediated knockdown of lncGRS-1 sensitizes malignant
glioma to the therapeutic effects of radiation in this 3D
model of tumor growth.
Discussion
In this study, we developed a CRISPRi-based pooled
screening platform to discover novel non-coding thera-
peutic targets in human malignant glioma that can en-
hance the efficacy of radiation therapy. Given that
CRISPRi is effective in a wide range of cancer cell types
[8], our work presents a conceptual and experimental
framework that can be used to rapidly interrogate new
targets in multiple, clinically relevant treatment combi-
nations (e.g., synthetic lethality with traditional chemo-
therapy and/or radiation, or with newer classes of
targeted therapeutics). The prioritization of combinator-
ial therapeutic targets for preclinical development is in-
creasingly needed, particularly for malignant glioma
[58–60]. While we focused on lncRNAs as potential
therapeutic targets in glioma, the overall strategy de-
scribed here could be easily adapted to screen other
types of non-coding genomic elements as well as coding
genes.
The interaction between radiation treatment and any
particular biological target can be difficult to predict, espe-
cially when the mechanism of action of the target is not
fully understood. In our study of lncRNAs, of the 467
screen hits that reduced the growth of irradiated GBM
cells, only 33 hits behaved as sensitizers (having effect
sizes greater with fractionated radiotherapy than without
radiation). Interestingly, some lncRNA hits that reduced
the growth of non-irradiated GBM cells appeared to
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Fig. 6 Tumor-specific, radiosensitizing function of lncGRS-1 knockdown in mature brain organoids (MBOs). a Schematic of MBO assembly from
induced mature astrocytes (iAstrocytes) and induced neurons (i3Neurons). b Single molecule RNA FISH of lncGRS-1 in iAstrocyte MBO (A-MBO)
cells following transfection of non-targeting ASO (top) or ASO targeting lncGRS-1 (bottom). Scale bar = 5 μm. c RT-qPCR of lncGRS-1 in A-MBOs
seeded with DIPG SF8628 following ASO transfection (n = 2 biological replicates per condition; error bar = SD). d Left, fluorescence viability assay
of A-MBOs following transfection of non-targeting ASO or ASO targeting lncGRS-1. Right, apoptosis induction assay of A-MBOs following
transfection of ASOs (n = 2 biological replicates per condition; error bar = SD). e Schematic of RFP+ glioma cell seeding and subsequent RFP+
tumor growth over time. f, g Longitudinal fluorescence microscopy of A-MBOs seeded with RFP+ DIPG SF8628 cells treated with non-targeting
Ctrl ASO (f) or ASO targeting lncGRS-1 (g). h, i Quantification of RFP+ tumor burden (h) and organoid diameter (i) in longitudinal analysis of A-
MBOs seeded with RFP+ DIPG SF8628 cells (n = 6 biological replicates per condition; two-tailed Student’s t test). j Quantification of RFP+ U87
GBM tumor burden in iAstrocyte and i3Neuron MBOs (AN-MBOs) treated with ASOs with or without radiation (n = 5 biological replicates per
condition; two-tailed Student’s t test). Boxplots represent 1st quartile, median, and 3rd quartile with whiskers = range
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ameliorate the effect of radiation (Fig. 2c). These results
highlight the importance of unbiased functional genomic
methods such as CRISPRi-based pooled screening, par-
ticularly when investigating new classes of potential thera-
peutic targets.
Our systematic approach prioritized lncGRS-1 as a top
radiation sensitizer for malignant glioma. Knockdown of
lncGRS-1 with either CRISPRi or ASOs inhibited the
growth of both adult and pediatric forms of malignant
glioma, potentiating the therapeutic effects of clinically
relevant doses of fractionated radiotherapy. Therefore,
lncGRS-1 shares properties both of an essential gene that
is required for normal growth and also a radiation
sensitizer target. However, despite being expressed in
non-malignant brain cells, lncGRS-1 knockdown did not
appear to adversely affect their viability or growth. Of
particular note, ASO-mediated knockdown of lncGRS-1
in NHA—cells that proliferate as briskly as the patient-
derived glioma cells—did not impair the growth of this
non-malignant glial cell type, nor did lncGRS-1 knock-
down affect growth of the malignant but non-glioma cell
line HeLa. While the transcriptomes of GBM and DIPG
cells were broadly perturbed by lncGRS-1 knockdown,
only 17 genes were differentially expressed (with
lncGRS-1 being the most significant) in NHAs with the
same ASO-mediated knockdown. The mechanisms
underlying this glioma-specific function of lncGRS-1 re-
main to be discovered, but upon lncGRS-1 knockdown,
we did observe activation of the p53 signaling pathway
leading to upregulation of p53 effectors such as p21, cor-
relating with a decrease in cell cycle progression. Our
observations here build importantly on previous
genome-scale studies that reveal essential lncRNAs as
having exquisitely cell type-specific function [8, 61, 62].
Based on this emerging understanding of lncRNA biol-
ogy, we speculate that lncRNAs as a class are enriched
for targets that have important roles selectively in malig-
nant cells.
Modeling human glioma in mice as transplanted xeno-
grafts is time-consuming and relatively expensive, par-
ticularly for early preclinical studies intended to screen
new drugs for therapeutic efficacy and potential toxicity
[25]. Furthermore, certain human therapeutic targets do
not exist in animal hosts—as is the case for lncGRS-1—
decreasing the utility of animal models for assessing po-
tential toxicity stemming from the ablation of such tar-
gets in normal tissue. Human organoids represent a
medium-throughput platform for cancer studies [63],
and our studies demonstrate the utility of MBOs for
simultaneously evaluating treatment efficacy and brain
toxicity, including in the context of current radiotherapy
treatment paradigms.
As a 3D tissue platform for the study of human gli-
oma, MBOs offer certain characteristics that distinguish
them from embryonic brain organoids and GBM-derived
tumor organoids. In contrast to embryonic brain organoids
that mimic early stages of fetal brain development, MBOs
are assembled from cell populations that are more mature
and postmitotic [54, 55]. Because embryonic brain orga-
noids contain a large proportion of proliferative precursor
cells, radiation treatment and/or other traditional chemo-
therapies may not be well-tolerated by such normal but im-
mature cells. GBM-derived tumor organoids are useful for
the study of drug efficacy in 3D tissues, but because they
are comprised of only tumor cells, toxicity to normal cells
and therefore the therapeutic index [64] cannot be assessed.
Because of these differences, it is likely that each organoid
platform will have important utility in different preclinical
research scenarios. As a bridge between in vitro and in vivo
preclinical experiments intended to prioritize drug candi-
dates and therapeutic targets, MBOs have shown utility in
our study, identifying lncGRS-1 as a target for further pre-
clinical development such as in vivo validation. One limita-
tion of our MBO-glioma model is the absence of a
complete tumor microenvironment, which includes micro-
glia, stromal cells, and tumor-infiltrating lymphocytes,
among other cell types [65, 66]. However, recent advances
in tumor organoid derivation have demonstrated preserva-
tion of syngeneic tumor-infiltrating lymphocytes and stro-
mal fibroblasts along with neoplastic cells using an air
liquid interface [67]. Analogous strategies, in addition to
the incorporation of vascular endothelial cells, may further
augment the experimental utility of MBOs in future
iterations.
Conclusions
There is an unmet need for cancer therapies that po-
tentiate the therapeutic effects of radiation therapy while
minimizing toxicity [59]. Radiation therapy is one of the
most common treatment modalities for all cancers, and
it is nearly always indicated for patients with malignant
glioma [23]. The development of drug-radiotherapy
combinations has generally been pursued with low-
throughput, non-systematic approaches [60]. Our
genome-scale CRISPRi-based radiation modifier screen
of lncRNA loci in glioma demonstrates a strategy for re-
vealing novel therapeutic targets in this vast, largely un-
explored aspect of the non-coding genome. More
broadly, we anticipate that the coupling of large-scale
screening efforts with target validation in MBO models
will serve as a useful framework for accelerating the de-
velopment of new therapeutics (and combinations)
through the preclinical research pipeline.
Methods
Cell culture and radiation treatment
U87, NHA, and HEK293T cells were grown in DMEM
with 10% FBS and antibiotics/antimycotics. DIPG SF8628,
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GBM SF10360, and GBM 43 were cultured in N5 (Neuro-
basal-A (1×), N2 (1×), B27 supplement without vitamin A
(1×), L-glutamine (1×)), 5% FBS, and FGF and EGF (20 ng/
mL each). SU-DIPG 24 and SU-DIPG 25 were cultured in
TSM (Neurobasal-A (1×), DMEM/F12 (1×), HEPES (10
mM), sodium pyruvate (1mM), MEM non-essential
amino acids solution (0.1mM), GlutaMax supplement
(1×), antibiotic-antimycotic (1×)) with EGF (20 ng/mL),
FGF-basic-154 (20 ng/mL), PDGF-AA (10 ng/mL), PDGF-
BB (10 ng/mL), and heparin (2 μg/mL). Proliferation was
measured using a manual hemocytometer. Cell viability
was measured using the CellTiter-Blue Cell Viability
Assay (Promega), and apoptosis was measured using the
Apo-ONE Homogenous Caspase-3/7 Assay (Promega).
Radiation was delivered using a Cesium-137 irradiator
with rotating platform, with cells treated while in suspen-
sion for the CRISPRi screen and after achieving adherence
on plates for validation assays.
Determination of radiation synergy was calculated as
follows. The null model of additive effects was deter-
mined by multiplying the mean decrease in cell prolifer-
ation caused by radiation treatment alone by the
decrease in cell proliferation following gene knockdown.
Synergistic effects were identified if the observed abso-
lute decrease in cell proliferation following combination
of lncRNA knockdown and radiation was significantly
greater than the predicted decrease in cell proliferation
based on the additive model (two-tailed Student’s t test).
CRISPRi screens
sgRNA library was derived from the CRISPRi Non-
Coding Library (CRiNCL) [8], selecting sub-libraries that
targeted all expressed lncRNAs in U87: Common + Can-
cer common + (U87, HEK293T) + U87 unique. sgRNAs
were cloned into the library expression vector
pCRISPRia-v2 [11, 68], and lentivirus pools were gener-
ated as previously described [8]. U87-dCas9-KRAB cells
were generated previously in [69]. Lentivirus libraries were
infected in duplicate cultures, cultured for 2 days following
infection, puromycin (1mg/mL) selected for 2 days, and
recovered for 1 day without puromycin. Cells were then
cultured for 12 days at a minimum coverage of 1000×,
starting at this “T0.” For the radiation modifier screen,
doses of 2 Gy radiation were given at the following days:
T0, T2, T4, and T6, for a total of 8 Gy fractionated ioniz-
ing radiation. Genomic DNA was harvested from aliquots
of ~ 60M cells each from T0 and T12 and processed for
sequencing as previously described [11, 68]. Data process-
ing and hit analysis was performed as described in [8],
with the exception that neighbor hits were considered to
be hits whose TSS were within 1 kb of any protein coding
gene TSS expressed in U87. Growth-only screen data for
U87 was obtained from [8] and compared to the radiation
screen data obtained in this study. For the identification of
radiation sensitizers, the screen scores (defined as the
average phenotype of the top three sgRNAs against a
given gene multiplied by the negative log10(Mann-Whit-
ney U p value) for that gene) for the radiation screen was
compared to those of the growth screen for all genes tar-
geted in both screens. Phenotype in these CRISPRi screens
refer to the relative log2 enrichment of barcodes in the
final timepoint divided by the enrichment of barcodes
at the initial timepoint, as has been previously de-
scribed [8, 11]. A screen score threshold of 5, which
corresponded to an empirical false discovery rate of
0.25%, was applied to both screens, and hits with ra-
diation scores greater than growth scores were
retained. LncRNAs with evidence of expression in pri-
mary glioma cells were then identified as lncGRS. Z
standardized growth and radiation phenotypes were
calculated as log2 enrichment normalized by the
standard deviation of negative control genes’ pheno-
types. Sensitizer score was defined as the ratio of the
radiation modifier screen score in irradiated cells to
the growth screen score in non-irradiated cells.
sgRNA validation and internally controlled growth as-
says was performed as described in [8], with the addition
of 4 fractions of 2 Gy radiation starting 2 days following
sgRNA infection, delivered every other day. Purified
populations of sgRNA-expressing cells were selected in
1 mg/mL puromycin for 3 days before assay. Internally
controlled CRISPRi growth assays were performed as
previously described, briefly, by partially infecting a
population of cells stably expressing dCas9-KRAB with a
fluorescently labeled sgRNA expression vector and
tracking the sgRNA-infected population over time using
flow cytometry relative to the non-infected population
[8]. sgRNA protospacer sequences for individual knock-
downs are listed in Table S2.
RT-qPCR
RNA was harvested in TRIzol at 24 h following ASO
transfection, or in the case of CRISPRi, 72 h following
initiation of puromycin selection for sgRNA expression.
RNA was purified using the Direct-zol MiniPrep or
MicroPrep RNA purification kits (Zymo Research) with
the on-column DNAse digestion step. cDNA was gener-
ated using the Transcriptor First Strand cDNA Synthesis
Kit (Roche) and diluted 1:5 fold before proceeding to
qPCR. qPCR was performed using the SYBR Green I
Master Mix (Roche) on a LightCycler 480 instrument
(Roche). qPCR primers are listed in Table S2.
Subcellular fractionation
Cells were plated in a 15-cm dish and fractionated as
previously described [70]. Briefly, 10 to 20 million cells
were collected, washed with phosphate-buffered saline
(PBS), and resuspended at 4 × 107 cells/mL in buffer A
Liu et al. Genome Biology           (2020) 21:83 Page 12 of 18
(10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM MgCl2,
0.34M sucrose, 10% glycerol, 1 mM dithiothreitol, and
protease inhibitor cocktail [Boehringer]). Triton X-100
was added (0.1% final concentration), the cells were in-
cubated on ice for 8 min, and nuclei (fraction P1) were
collected by centrifugation (5 min, 1300×g, 4 °C). The
supernatant (fraction S1) was clarified by high-speed
centrifugation (5 min, 20,000×g, 4 °C), and the super-
natant (fraction S2) was collected. The P1 nuclei were
washed once in buffer A and lysed for 30 min in buffer B
(3 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol, and
protease inhibitor cocktail [Boehringer]), and insoluble
chromatin (fraction P3) and soluble (fraction S3) frac-
tions were separated by centrifugation (5 min, 1700×g,
4 °C). The P3 fraction was washed once with buffer B.
All the fractions obtained were resuspended in TRIzol
for RNA extraction, and qPCR was performed as de-
scribed above.
Single molecular FISH
ISH was performed on cell lines and MBOs using the
RNAscope 2.5 HD Assay—BROWN (Advanced Cell
Diagnostics). Probes targeting the lncGRS-1 transcript
were used (RNAscope Probe Hs-CTC-338M12.4, cata-
log number 300031). ISH was performed following the
manufacturer’s instructions.
Western blot
Cells were washed with PBS and lysed using RIPA buffer
supplemented with HALT protease inhibitor (78429;
ThermoFisher Scientific). The lysate was mixed (1:1)
with 2× NuPAGE LDS Sample Buffer and ran on
NuPAGE 10% Bis-Tris gel using NuPAGE MOPS SDS
Running Buffer. Proteins were transferred from gel to
Amersham Hybond PVDF membrane using NuPAGE
Transfer Buffer with 10% methanol. The membrane was
blocked for 1 h in Odyssey Blocking Buffer and incu-
bated overnight at 4 °C with primary antibodies—p21
(2947), 1:1000, and GAPDH_14C10(2118),1:1000, both
from Cell Signaling Technologies. Following 3× 10 min
washes with PBS+ 0.1% Tween, the membrane was
probed by the IRDye 800CW Goat anti-Rabbit IgG (926-
32211). Images were captured using LiCOR Odyssey In-
frared Imaging Systems and quantified using ImageJ.
Western blot intensities were normalized by their re-
spective loading controls and then normalized again to
the mean of the negative control conditions.
Immunohistochemistry for P53BP1 and γH2AX
Cells were plated in 8-well chambered slides (Thermo
Scientific Nunc 154526) at a density of ~ 10,000 cells/
cm2 and cultured overnight. Each chamber was trans-
fected with either control ASO or lncGRS-1 ASO and
then irradiated at 2 Gy. Cells were fixed 6 h following
radiation with 4% paraformaldehyde for 15 min at room
temperature. They were further incubated in
permeabilization reagent (0.1% Triton-X100 in TBS) for
15 min at room temperature. Cells were blocked in
blocking solution (10% Normal Donkey Serum in TBS)
for 1.5 h in a humidified chamber. Cells were incubated
in primary antibody solution anti-rabbit Phospho-53BP1
(Ser1778, Cell Signaling Technologies) at a 1:100 con-
centration and anti-rabbit γH2AX (Ser139, Cell Signal-
ing Technologies) at a 1:400 concentration. Plates were
incubated overnight at 4 °C. Cells were washed in PBST,
and secondary antibody and DAPI were added (Alexa
488 for P53BP1 and Alexa 594 for γH2AX) at a 1:1000
concentration. Plates were incubated for 2 h at room
temperature in a humidified chamber away from light.
Slides were washed and mounted with Aqua-PolyMount.
Slides were left to dry in the dark at room temperature
for 3 h. Images were acquired at room temperature on
an SP3 Leica Confocal microscope using × 63 oil object-
ive and processed using ImageJ.
Flow cytometry for cell cycle analysis
Cells were transfected with ASOs as described below.
After 72 h, cells were pulsed with 33 μM bromodeoxyur-
idine (BrdU) for 20 min, and afterwards fixed in 70%
ethanol. Cells were then stained with primary anti-BrdU
antibody (Clone B44; BD Biosciences) for 1 h, followed
by 1 h incubation with Alexa Fluor 488 anti-mouse IgG
(Invitrogen). DNA was counterstained using 0.1 mg/mL
propidium iodide supplemented with RNase for 1 h at
37 °C. Analysis was performed on a FACSCalibur using
CellQuest (BD). Quantification and analysis of cell cycle
profiles were performed using FlowJo (Tree Star, Inc).
Antisense oligonucleotides
Locked nucleic acid antisense oligonucleotides were de-
signed using the Qiagen custom LNA oligonucleotides
designer. ASOs were transfected at a final concentration
of 50 nM using the Lipofectamine RNAiMAX Reagent
using the manufacturer’s instructions (Thermo). Three
ASOs were tested, and the top two based on knockdown
efficiency were used for subsequent studies. For orga-
noid transfection experiments, the ASO with the highest
knockdown efficiency was used. For ASO penetration
control studies, 5′-FAM-labeled ASOs of negative con-
trol ASO A were used (Qiagen). ASO target sequences
are listed in Table S2.
Nanopore direct RNA sequencing
Total RNA was isolated from U87 human glioblastoma
cells using TRI Reagent Solution (ThermoFisher), followed
by bead-based poly(A) selection. Approximately 750 ng of
poly(A) RNA was used for dT adapter ligation, followed by
reverse transcription, and additional ligation of motor
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adapter prior to loading onto the Oxford Nanopore Tech-
nologies (ONT) PromethION for sequencing. The ionic
current trace for each poly(A) RNA strand was base called
using the ONT Guppy algorithm.
RNA-seq sample preparation and data analysis
For U87 radiation assays, RNA was harvested using TRI-
zol 48 h following radiation treatment and purified using
the Direct-zol MiniPrep RNA purification kits (Zymo Re-
search) with the on-column DNAse digestion step. For
ASO assays followed by RNA-seq, RNA was harvested at
24 h following ASO transfection. RNA integrity was con-
firmed using the Agilent Bioanalyzer. RNA-seq libraries
were generated using TruSeq Stranded mRNA kit accord-
ing to the manufacturer’s protocol (Illumina). cDNA was
validated using the Agilent Bioanalyzer, Qubit 2.0
Fluorometer (Life Technologies), and ddPCR (Bio-Rad).
Cluster generation and sequencing was performed on a
HiSeq 2500, using the paired end 100 read protocol.
Reads were aligned to the human genome (GRCh38)
using the spliced read aligner HISAT2 v2.0.3 [71] against
an index containing SNP and transcript information
(genome_snp_tran). Quantification of Ensembl build 75
genes was carried out with featureCounts [72] using only
uniquely mapped reads. Differential expression analysis
was performed using DESeq2 [73] using the Wald test
with an adjusted (multiple hypothesis corrected) p value
threshold of 0.05 as threshold for differential expression.
Complete linkage hierarchical clustering was performed
using 1 – Pearson’s correlation coefficients as the dis-
tance matrix, using only differentially expressed genes or
differentially expressed lncRNAs. Gene ontology terms
were obtained using Enrichr [74], taking gene names
from the clusters of all upregulated or downregulated
genes. Analysis was performed using R version 3.6.
Mature brain organoids and tumor co-cultures
Generation of iAstrocytes
WTC11 human iPSCs were directed towards a cortical
astrocyte fate as previously described [54, 55]. Briefly,
iPSCs were dissociated and reformed as embryoid bod-
ies; dual SMAD inhibition was used to initiate neural in-
duction using SB431542 and DMH1 (2 μM each) in
defined media composed of DMEM F12, GlutaMax, so-
dium bicarbonate, sodium pyruvate, and N2 and B27
supplements. Once neuroepithelial cells were isolated,
cultures were maintained in suspension for ~ 180 days
using defined media composition detailed above plus
EGF and FGFb (10 ng/mL each) to drive proliferation
and maturation into cortical astrocytes.
Generation of i3Neurons
WTC11 human iPSCs containing a transgenic doxycyc-
line inducible cassette of NEUROG2 were induced into
neurons as previously described [75]. Briefly, iPSCs were
treated with doxycycline (2 μg/mL) in a defined media
composed of DMEM F12, N2 supplement, non-essential
amino acids, and GlutaMax for 3 days. Populations were
characterized as postmitotic and expressing MAP 2 and
βIII-Tubulin to validate neuronal induction efficiency.
Generation of MBO cultures
Combined iAstrocyte and i3Neuron mature organoid
(AN-MBO) cultures were generated by combining iPSC-
derived iAstrocytes and iPSC-derived i3Neuron at a ratio
of 1:1 (iAstrocytes to i3Neurons), unless otherwise speci-
fied, in single cell suspension. Both iAstrocytes and i3Neu-
rons were isogenic and derived from WTC11 human
iPSCs. iAstrocyte mature organoids (A-MBO) were gener-
ated with iAstrocytes alone after 6–8months generation
time. Organoid spheres were generated by introducing 10,
000–20,000 composite cells onto spheroid microplates
(Corning). MBO cultures were prepared by combining de-
sired cells types in single cell suspension and aliquoting
the specified concentration across multiple wells of spher-
oid microplates (Corning). Microplates were then centri-
fuged at 300g for 3min. Organoids were allowed to
coalesce for ~ 48 h prior to the initiation of tumor cell
seeding. Organoid cultures were maintained in AM0
media—DMEM/F12, N2 supplement, B27 supplement,
GlutaMax, antibiotic-antimycotic (Gibco) to 1× the manu-
facturer’s recommended final concentrations, and heparin
(2 μg/mL, Sigma).
DIPG cell seeding and time course
DIPG SF8628 cells labeled with lentiviral red fluorescent
protein (RFP) were added as single cell suspension dir-
ectly into 96-well plates, with each well containing a sin-
gle pre-formed A-MBO, at a ratio of 1:5 (tumor cell to
non-tumor cell). Tumor cells were seeded by pipetting
directly into the culture media, and therefore, only a
small proportion of tumor cells invaded each organoid
after seeding (presumably only those cells that landed
directly on top of the organoid). Twenty-four hours fol-
lowing the seeding of DIPG cells onto A-MBOs, co-
cultures were transfected with ASO (50 nM) and re-
peated once every 7 days. Co-cultures were maintained
in AM0 with EGF and FGFb (20 ng/mL each). Growth-
arrested DIPG A-MBO co-cultures used for radiation
dose testing were maintained in AM0 without growth
factors. Phase contrast and fluorescence images were ob-
tained by focusing on a central Z-plane through the cen-
ter of each organoid using a Leica DMI4000 B
fluorescence microscope.
U87 cell seeding and time course
AN-MBOs comprised of 1:1 (iAstrocytes to i3Neurons)
at 10,000 cells of each type were prepared before tumor
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cell seeding. AN-MBOs were allowed to mature for 2–3
weeks in AM0. GBM U87 cells labeled with lentiviral
RFP (3500 cells per co-culture) were added as single cell
suspension directly into 96-well plates, with each well
containing a single pre-formed AN-MBO. Twenty-four
hours following the seeding of GBM U87 cells onto AN-
MBOs, co-cultures were transfected with ASO (50 nM)
and repeated once every 7 days. Co-cultures were main-
tained in AM0 without growth factors. Phase contrast
and fluorescence images were obtained by focusing on a
central Z-plane through the center of each organoid
using a Leica DMI4000 B fluorescence microscope.
Tumor burden quantification
Two-dimensional fluorescence images acquired through
the central focal plane of each organoid sphere were an-
alyzed using ImageJ (Version 1.51 m9, NIH). The two-
dimensional region of interest encompassing the MBO
with tumor co-culture was calculated by manual selec-
tion of the sphere. The two-dimensional size of the
RFP+ tumor infiltrate within the interior of each orga-
noid was quantified by thresholding the fluorescence in-
tensity to exclude non-tumor infiltrated regions and
tumor-free organoids and excluding any RFP+ regions
that fall outside the spherical boundaries of the total
organoid co-culture surface area. Thresholding was per-
formed in an unbiased manner with the same color in-
tensity applied across replicates and timepoints.
Organoid preparation for confocal imaging
MBOs were fixed using 4% paraformaldehyde and incu-
bated at 4 °C for 60 min. Organoids were then washed
three times with PBS at room temperature, allowing 5
min incubation per wash. Organoids were then incu-
bated for 24 h at 4 °C in PBS with 30% (wt/vol) sucrose.
Organoids were embedded in disposable base molds
(Fisherbrand #22363552) using embedding solution (1:1,
OCT:30% sucrose solution). Embedded organoids were
frozen and sliced using a cryotome producing 15 μm
sections and mounted on microscopy slides. Imaging
was performed using a Leica TCS SP5 X confocal micro-
scope and analyzed in ImageJ.
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Additional file 1: Figure S1. (a) Transcriptomic analysis of radiation
response. RNA-seq analysis of differentially expressed genes following
single dose radiation of U87 cells, along with significant gene ontology
terms for upregulated and downregulated genes (n = 2-3 biological
replicates per condition). (b) Log2 fold change of lncGRS-1 in U87 cells
following radiation, averaged across all replicates from the same
condition. Figure S2. Properties of the CRISPRi radiation modifier screen.
(a) Proportion of two replicates of the screen population that are
expressing sgRNA (BFP positive). Puromycin selection time period
highlighted in yellow. Radiation doses indicated by arrows. (b) Z
standardized growth (no radiation) and radiation phenotypes for PVT1 in
CRISPRi screens. (c) Comparison of z standardized radiation phenotypes
(x-axis) and log2 fold change of targeted lncRNA expression from RNA-
seq (y-axis) analysis. Z standardized phenotypes were calculated as log2
enrichment normalized by the standard deviation of negative control
genes’ phenotypes. lncGRS-1 to lncGRS-9 are labeled by their NCBI gene
names. Figure S3. Nanopore direct RNA-seq of spliced reads aligned to
the lncGRS-1 through -9 loci in U87 cells, with GENCODE v29 transcript
models, Ensembl H3K27Ac layered track, and multiz alignment for
conservation (from top to bottom in each subpanel). Figure S4. ASO
knockdown of lncGRS-1 demonstrating glioma specific phenotype. (a)
Single molecule RNA FISH of lncGRS-1 in DIPG SF8628 cells following
transfection of non-targeting ASO (top) or ASO targeting lncGRS-1
(bottom). Scale bar = 5 μm. (b) RT-qPCR of TP53 (p53) transcript levels
following ASO knockdown of TP53 in U87 cells. (c) lncGRS-1 locus with
locations of sgRNA, ASO, and qPCR primer targets. (d-g) RT-qPCR of
lncGRS-1 transcript levels (left) and cell propagation assay (right)
following ASO knockdown of lncGRS-1 in SU-DIPG 24 (d), SU-DIPG 25
(e), GBM 43 (f), and HEK293T cells (g). (h) RT-qPCR of POLA1 transcript
levels (left) and cell proliferation assay (right) following ASO knockdown
of NHA cells (at day 7) or in (i) U87 cells (at day 3). n = 2 - 3 biological
replicates per condition in all experiments indicated; error bar = S.D.
Figure S5. (a) Cell propagation assay of purified populations of HeLa
cells with lncGRS-1 CRISPRi knockdown. (b) Expression values (log2 (TPM
+ 1)) of lncGRS-1 across cell lines in the CCLE atlas, grouped by disease
of origin or tissue type. (c) Top 5 gene ontology terms for upregulated
(top) and downregulated (bottom) differentially expressed genes with
adj. p val < 0.05, in GBM U87 (left) and DIPG SF8628 (right) 24 hours
following lncGRS-1 ASO-mediated knockdown. (d) Scatter plot of genes
differentially expressed in either U87 or SF8628 cell lines demonstrating
positive correlation in expression changes following lncGRS-1 knockdown.
(e) RNA-seq expression values and (f) western blot of protein levels for
CDKN1A (p21) with quantification (right) in U87 cells following lncGRS-1
knockdown. (g) Immunohistochemistry of p53BP1 and (h) γH2AX nuclear
foci in nuclei of U87 cells following lncGRS-1 knockdown with or without
2 Gy radiation. Scale bar = 5 μm. n = range of 225 to 440 nuclei per
replicate across 2 biological replicates per condition. Figure S6. Full size
western blot with additional replicate, corresponding to Figure S5f.
Figure S7. Radiosensitization of glioma cells in MBO hosts. (a)
Quantification of single molecule RNA FISH of lncGRS-1 in iAstrocyte
MBO (A-MBO) nuclei following transfection of non-targeting ASO or ASO
targeting lncGRS-1. n = 69 and 98 A-MBO nuclei quantified in ASO-Ctrl
and ASO #2 conditions, respectively, across 2 independent experiments
for each biological condition. (b) Left, fluorescence viability assay of
combined (1:1 ratio) iAstrocyte and i3Neuron organoids (AN-MBO)
following transfection of non-targeting ASO or ASO targeting lncGRS-1.
Right, apoptosis induction assay of AN-MBOs following transfection of
non-targeting ASO or ASO targeting lncGRS-1. (n = 3 biological replicates
per condition; error bar = S.D.). (c) Fold change in AN-MBO size between
day 2 and day 21 of co-culture with growth arrested DIPG SF8628 cells,
with negative control or lncGRS-1 ASO, at various doses of fractionated
radiation. (n = 5 biological replicates per condition; boxplot represents
1st quartile, median, and 3rd quartile with whiskers = range). (d) Confocal
microscopy of AN-MBO 20 days following seeding of RFP+ U87 glioma
cells. Nuclei are counterstained with DAPI (blue). Scale bar = 100 μm. (e)
Longitudinal fluorescence microscopy of individual AN-MBOs seeded
with RFP+ U87 cells. Cultures were treated with non-targeting ASO (Ctrl)
or ASO targeting lncGRS-1 combined with 0 Gy, 12 Gy, or 18 Gy of
fractionated radiation.
Additional file 2: Table S1. CRISPRi radiation screen results using
sgRNAs from the CRISPRi Non-Coding Library.
Additional file 3: Table S2. CRISPRi sgRNA protospacer sequences
used for individual knockdown, qPCR primers used, and ASO targeting
sequences.
Additional file 4: Table S3. DESeq2 output of differentially expressed
genes following ASO knockdown of lncGRS-1 compared to negative
control ASO in GBM U87, DIPG SF8628, and NHA cells.
Additional file 5: Review history.
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